Bass/Spangenberg file new pharma IPR re-exams
Hedge fund investor Kyle Bass and former IPNav CEO Erich Spangenberg have filed inter partes reviews against patents owned by Shire Pharmaceuticals and NPS Pharmaceuticals. The Irish headquartered Shire recently bought NPS in a $5.2bn deal. Its…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.